Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode Gets CE Mark for MDx Platform, GI Panel

NEW YORK (GenomeWeb) – Applied BioCode announced today that it has received CE mark certification for its BioCode MDx 3000 molecular testing platform and Gastrointestinal Pathogen Panel (GPP).

The BioCode MDx-3000 is a high-volume, automated PCR-based molecular diagnostics platform designed for use by large hospitals and reference labs. The system can process up to 94 samples in about 3.5 hours, or up to 3,384 results in an 8-hour shift, the Santa Fe Springs, California-based firm said.

The GPP tests for nucleic acids of 18 common bacteria, viruses, and parasites that cause infectious diarrhea.

Earlier this year, Applied BioCode submitted the platform and test to US regulators for clearance.

"Our system will help hospitals and clinical laboratories to provide high-volume syndromic testing to their patients at a more affordable cost," Applied BioCode President Winston Ho said in a statement. "The GI Pathogen Panel is the first of many syndromic panels we expect to bring to our customers."

Applied BioCode is developing additional infectious disease tests including ones for respiratory and sexually transmitted infections.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.